The government has set the maximum single exit price for medicines in 2026 at 1.47% — an adjustment that’s less than half of what the pharmaceutical industry had expected. Business Day TV spoke to Aspen’s group senior executive for strategic trade, Stavros Nicolaou, for insight into how the sector plans to respond.
